DRMA Stock Forecast: Dermata Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Dermata Therapeutics, Inc. is $2. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 26 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Dermata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (87): Analysts have, on balance, been raising their forecasts.
Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DRMA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DRMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Aug 2025 | Maxim Group | Maintains | Buy | $30 → $10 |
| 21 May 2025 | Maxim Group | Maintains | Buy | — |
| 21 Aug 2024 | Maxim Group | Maintains | Buy | — |
| 23 Mar 2023 | Maxim Group | Maintains | Buy | — |
| 21 Sept 2021 | Brookline Capital | Initiates | Buy | $14 |
| 14 Sept 2021 | Maxim Group | Initiates | Buy | $9.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DRMA.
This page is one stock. Monday covers all of them.
DRMA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DRMA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Dermata Therapeutics, Inc. returned −79.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DRMA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 35.9×
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 5% of US stocks
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −241.5%
- Return on assets
- −103.6%
- Dividend yield
- —
Higher than 6% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Dermata Therapeutics, Inc. has a market value of $2.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.4M.
Free cash flow in the twelve months to 30 June 2026: −$8.1M.
Dermata Therapeutics, Inc. employs 9 people.
Data provided by Twelve Data
DRMA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DRMA’s peer groups, ranked by the model: consumer staples stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Dermata Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DRMA
What is the DRMA stock price forecast for 2026-2027?
The median 12-month analyst price target for Dermata Therapeutics, Inc. is $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DRMA stock a buy right now?
Of the 1 analyst covering Dermata Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dermata Therapeutics, Inc. 26 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DRMA?
As at 21 Nov 2026, Dermata Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (87 of 100).
Will DRMA stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $2, and Ticker Nerd's factor model ranks Dermata Therapeutics, Inc. 26 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DRMA stock forecast for 2030?
No analyst covering Dermata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
How has DRMA stock performed over the past year?
Dermata Therapeutics, Inc. returned -79.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Dermata Therapeutics, Inc. do?
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions. The company currently works on topical dermatologic solutions that leverage its proprietary technology platform to target a range of skin disorders and cosmetic applications.
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions. The company currently works on topical dermatologic solutions that leverage its proprietary technology platform to target a range of skin disorders and cosmetic applications. Its product pipeline includes treatments designed for conditions such as acne, psoriasis, rosacea, and hyperhidrosis, as well as needle-free intradermal delivery approaches for aesthetic uses. Dermata Therapeutics also operates in the direct-to-consumer skincare market through the Tome brand, reflecting its broader emphasis on skin renewal and everyday dermatologic care. Headquartered in San Diego, California, Dermata Therapeutics serves as a specialized participant in the dermatology market, combining pharmaceutical development with consumer skincare products aimed at skin health and appearance.
CEO Mr. Gerald T. Proehl · 9 employees · United States · https://www.dermatarx.com